Unraveling the Potential of Isorhamnetin as an Adjuvant in Depression Treatment with Escitalopram

Oxidative stress and inflammation are implicated in depression. While selective serotonin reuptake inhibitors (SSRIs) like escitalopram are commonly prescribed as first-line treatments, their inconsistent efficacy and delayed onset of action necessitates the exploration of adjunctive therapies. Isor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammoh, Omar, Qnais, Esam Y., Athamneh, Rabaa Y., Al-Jaidi, Bilal, Al-Tawalbeh, Deniz, Altaber, Sara, Alqudah, Abdelrahim, Aljabali, Alaa A. A., Tambuwala, Murtaza M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530211/
https://www.ncbi.nlm.nih.gov/pubmed/37754268
http://dx.doi.org/10.3390/cimb45090484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530211/
https://www.ncbi.nlm.nih.gov/pubmed/37754268
http://dx.doi.org/10.3390/cimb45090484

Ejemplares similares